LCM
DYN icon

Laurion Capital Management’s Dyne Therapeutics DYN Stock Holding History

Laurion Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$5.32M – 547
2023
Q4 		$5.32M Buy
+400,000
New +$3.91M 0.05% 242

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Laurion Capital Management's DYN Position: Q1 2024 in Review

Laurion Capital Management sold out of Dyne Therapeutics (DYN) in Q1 2024, closing a stake of 400,000 shares — an estimated $5.32M sold.

Laurion Capital Management first reported a position in DYN in Q4 2023 and held it in 1 quarter. The position peaked at $5.32M in Q4 2023. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • Laurion Capital Management reported no remaining Dyne Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Laurion Capital Management sold 400,000 Dyne Therapeutics shares in Q1 2024, an estimated $5.32M.
  • Laurion Capital Management first reported a position in Dyne Therapeutics in Q4 2023 and held it in 1 quarter.
  • Laurion Capital Management's Dyne Therapeutics position peaked at $5.32M in Q4 2023.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.